Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
27 juin 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The Insight Partners
22 juil. 2022 07h35 HE
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
DelveInsight Estimates a Promising Picture of Pompe Disease Pipeline Landscape in the Coming Years as Key Pharma Companies Bolster Rare Disease Pipeline
15 sept. 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Sept. 15, 2021 (GLOBE NEWSWIRE) -- DelveInsight Estimates a Promising Picture of Pompe Disease Pipeline Landscape in the Coming Years as Key Pharma Companies Bolster Rare Disease...
AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical Trials
29 janv. 2020 10h27 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced...
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
19 déc. 2019 08h25 HE
|
Asklepios BioPharmaceutical, Inc.
– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...
BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease at 34th Annual J.P. Morgan Annual Healthcare Conference
11 janv. 2016 11h30 HE
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced interim results from INSPIRE, a Phase 2 trial for reveglucosidase alfa, a fusion...
Cortex Pharmaceuticals, Inc. Announces Publication of Research Results on the Use of Ampakines CX1739 and CX717 in the Treatment of Respiratory Disorders
04 mai 2015 09h00 HE
|
Cortex Pharmaceuticals, Inc.
GLEN ROCK, N.J., May 4, 2015 (GLOBE NEWSWIRE) -- Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company") announces the recent publication of two key scientific papers co-authored by the...